Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

Let’s get straight to the point: a good nurse can change your experience with cancer and cancer treatment.

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...